



## **Texas Breast Specialists Adds Naviscan PEM Technology to Breast Cancer Treatment Services**

SAN DIEGO, Calif. and THE WOODLANDS, Texas – November 29, 2010 – Texas Breast Specialists, part of Texas Oncology, has expanded its breast cancer treatment services in Dallas, McKinney, Bedford, Carrollton, and Plano, Texas to include the mobile Naviscan PEM scanner. PEM (Positron Emission Mammography) scanners are high-resolution breast PET systems that show the location as well as the metabolic phase of a lesion. The metabolic view allows physicians to enhance their cancer care decision by providing an unprecedented ability to distinguish between benign and malignant lesions, what researchers term “specificity.”

Texas Breast Specialists and Texas Oncology, affiliates of the United Network of US Oncology, are committed to delivering high-quality cancer care with leading-edge technology and advanced treatment and therapy options that help patients achieve better outcomes. US Oncology, which supports the nation’s largest community-based cancer treatment and research network, continuously helps its affiliated practices invest in innovative technologies that improve the quality of care for patients. “We are excited to bring this level of technology to the community,” said Dr. Lynn Canavan, a breast surgeon with Texas Breast Specialists in McKinney and Plano, Texas. “The level of specificity provided by PEM enhances the services we provide to our patients.”

Results from an NIH-sponsored clinical study [NIH Grant 5R44CA103102], presented today at the 2010 Radiological Society of North America, comparing PEM and breast MRI demonstrate PEM’s clinical appropriateness. The multi-site study of hundreds of women with newly diagnosed breast cancer shows that PEM demonstrated comparably high sensitivity but a six percent improvement in specificity, ability to differentiate between malignant and benign lesions, suggesting that PEM may reduce unnecessary biopsies. These results are particularly significant for women who cannot tolerate an MRI exam and require an alternate imaging tool. The study is slated for publication in the January issue of the journal *Radiology* and already available online.

“Naviscan is extremely excited to be developing a relationship with US Oncology and its affiliated practices,” said Paul J. Mirabella, Chairman and CEO, Naviscan, Inc. “US Oncology and its Texas Oncology partners have led the market in innovative approaches to the management and treatment of breast cancer. Because of the unique characteristics of our leadership in tomographic Molecular Breast Imaging technology, physicians in this network will now be able to make the best possible surgical decisions and the Medical



Oncologists will be able to see the impact of chemotherapy treatment after one application of therapy. This will provide the best and most cost effective course of treatment for patients, providers and payors.”

### **About Texas Breast Specialists and Texas Oncology**

Texas Breast Specialists provides surgical and radiological services for the treatment of diseases of the breast. Texas Breast Specialists is a related practice of Texas Oncology, which delivers high-quality cancer care with leading-edge technology and advanced treatment and therapy options in their own communities. Texas Oncology, a pioneer in community-based cancer care, is an independent oncology practice with sites of service throughout Texas, southern New Mexico, and southeastern Oklahoma. Texas Urology Specialists is also a related practice of Texas Oncology.

Texas Oncology patients have the opportunity to take part in some of the most promising clinical trials in the nation for a broad range of cancers. Through its affiliation with US Oncology and the US Oncology Research network, Texas Oncology participates in innovative clinical trials from Phase I through Phase IV, and has played a role in the development of 43 Food and Drug Administration (FDA) approved cancer therapies. For more information, visit [www.TexasOncology.com](http://www.TexasOncology.com).

### **About US Oncology**

US Oncology, Inc. is the nation’s leading integrated oncology company. By uniting the largest community-based cancer treatment and research network in America, US Oncology expands patient access to high-quality care and advances the science of cancer care. Headquartered in The Woodlands, Texas, US Oncology is affiliated with 1,400 community-based oncologists, and works with patients, hospitals, payers, and the medical industry across all phases of the cancer research and delivery continuum. By promoting the use of innovative technology, clinical research, evidence-based medicine and shared best practices, US Oncology improves patient outcomes and offers a better patient experience. For more information, visit [www.usoncology.com](http://www.usoncology.com).

### **About Naviscan, Inc.**

Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PEM scanner is currently installed and available in breast and imaging centers throughout the U.S. and other parts of the world. The Company is headquartered in San Diego, California and is the first to obtain FDA-clearance for a high-resolution PET scanner designed to image small body parts and for breast biopsy



image guidance. For more information, call 1.858.587.3641 or visit [www.naviscan.com](http://www.naviscan.com)

**Contact Information**

Guillaume Bailliard  
Executive VP, Marketing  
Naviscan, Inc.  
Tel: (858) 332-0941  
[gbailliard@naviscan.com](mailto:gbailliard@naviscan.com)

Jennifer L. Horspool  
Director Corporate Communications  
US Oncology, Inc.  
Tel: (949) 933-4300  
[jennifer.horspool@usoncology.com](mailto:jennifer.horspool@usoncology.com)

###